Mardi Dier, who serves as Executive Vice President and Chief Financial Officer of Madrigal Pharmaceuticals (NASDAQ: MDGL), sold 1,183 shares of the company's common stock on March 2, 2026. The shares changed hands at $427.21 apiece, producing a total transaction value of $505,389.
Following the disposition, Dier retains direct ownership of 9,257 shares of Madrigal stock. The sale was carried out automatically to meet tax withholding obligations arising from the vesting of restricted stock units and was not executed at Dier's discretion.
At the time of reporting, Madrigal's shares were trading at $435.62. An InvestingPro analysis cited alongside the transaction indicates the company is viewed as undervalued relative to its Fair Value assessment.
Financial results for Madrigal's fourth quarter of 2025 painted a mixed picture. The company reported earnings per share of -$2.57, a substantial miss compared with the expected -$0.60. In contrast, Madrigal's revenue came in ahead of forecasts, totaling $321.1 million against an anticipated $310.82 million, signaling stronger top-line performance than analysts expected.
Market analysts responded to the quarterly disclosures by maintaining positive stances. Truist Securities reiterated a Buy rating and kept a price target of $640.00. H.C. Wainwright also reiterated a Buy rating and held a $620.00 price target, highlighting the commercial performance of Rezdiffra, which has generated nearly $1 billion in net sales.
For investors seeking expanded analysis, a comprehensive Pro Research Report covering Madrigal is available, as part of a suite that spans more than 1,400 U.S. equities. That resource is cited as a source for deeper coverage of the company's financial position and valuation.
The transaction by Dier, combined with the quarterly results and analyst commentary, presents investors with a set of facts to weigh: an automatic insider sale to meet tax requirements; a meaningful EPS shortfall; revenue that exceeded expectations; and continued analyst confidence reflected in reiterated Buy ratings and six-hundred-dollar range price targets.